- Kairos Pharma’s partnership with Cedars-Sinai Medical Center enhances clinical trial efficiency and accelerates the development of new therapeutic solutions.
- The company holds a robust intellectual property portfolio with patents extending through 2040, providing a strong competitive advantage in the oncology market.
- ENV105, Kairos’s lead drug candidate, shows promise in reversing drug resistance in prostate and lung cancers, addressing key markets with high demand for novel treatments.
- Positioned in high-growth oncology segments, Kairos Pharma meets substantial market needs, driven by the increasing global incidence of drug-resistant cancers.
- The company’s focus on biomarker development improves patient targeting, enhancing therapy success rates and underscoring its commitment to precision medicine.
Kairos Pharma (NYSE American: KAPA) is a clinical-stage biopharmaceutical company focused on advancing innovative oncology therapeutics that target drug resistance and immune suppression, two significant barriers in effective cancer treatment. By addressing these mechanisms, Kairos aims to restore the efficacy of standard cancer treatments while enhancing the body’s natural immune responses against tumors.
The company’s mission is to develop a diverse portfolio of drug candidates to provide novel options for patients with limited treatment pathways. Kairos is advancing its therapeutic pipeline with a focus on partnerships, precision medicine and clinical trial efficiency, moving closer to delivering new…
NOTE TO INVESTORS: The latest news and updates relating to KAPA are available in the company’s newsroom at https://ibn.fm/KAPA
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]
BioMedWire is powered by IBN